Top Suppliers:I want be here



150915-40-5

150915-40-5 structure
150915-40-5 structure
  • Name: Tirofiban hydrochloride
  • Chemical Name: tirofiban hydrochloride
  • CAS Number: 150915-40-5
  • Molecular Formula: C22H39ClN2O6S
  • Molecular Weight: 495.073
  • Catalog: API Circulatory system medication Prevention and treatment of angina pectoris
  • Create Date: 2018-02-21 08:00:00
  • Modify Date: 2024-01-02 09:12:15
  • Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistIC50 value:Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml).

Name tirofiban hydrochloride
Synonyms L 700462 MK 383 N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine
N-(butylsulfonyl)- O-[4-(4-piperidinyl)butyl]-L-tyrosine monohydrochloride monohydrate
N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]tyrosine hydrochloride hydrate
N-(Butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine hydrochloride hydrate
(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,hydrate,hydrochloride
Tirofiban hydrochloride
Tirofiban hydrochloride monohydrate
tirofiban hydrochloride anhydrous
Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, hydrochloride, hydrate (1:1:1)
Tirofiban Hydrochloride Hydrate
Tirofiban (hydrochloride monohydrate)
Description Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistIC50 value:Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml).
Related Catalog
References

[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.

[2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.

[3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.

[4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.

[5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

Boiling Point 611.7ºC at 760 mmHg
Melting Point 135-137ºC
Molecular Formula C22H39ClN2O6S
Molecular Weight 495.073
Flash Point 323.7ºC
Exact Mass 494.221741
PSA 122.34000
LogP 5.48870
Storage condition -20°C Freezer
Water Solubility DMSO: >12mg/mL at warmed to 60°C
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H315-H319-H335
Precautionary Statements P261-P305 + P351 + P338
Hazard Codes Xi
Risk Phrases 36/37/38
Safety Phrases 26-37-45
RIDADR NONH for all modes of transport